Summary of the year since receiving the Start-Up Med 2022 award. Interview with Jarosław Biliński, MD, PhD for Rynekzdrowia.pl

At the beginning of 2022, we won the highest award in the Start-Up category with our project, the aim of which was to create a specialized preparation of gut bacteria (gut microbiota) to fight Clostridioides difficile infections, causing, among others, severe infection of the large intestine. The Human Biome Institute also presented plans to build a strong biotech company developing drugs to fight the “problem of the century” – antibiotic resistance of bacteria.

The passing year was a period of a very intensive work. We have built a team to create a computational laboratory that uses artificial intelligence and machine learning to predict the composition of drugs based on the microbiota. Drug Discovery platform is ready and in a couple days we will know the composition of the first biotherapeutic, treating C. difficile infections. The next will be the flagship one – for antibiotic-resistant infections.

Two more – an immunomodulatory biotherapeutic to help treat cancer and autoimmune complications, and a biotherapeutic to extend life (‘longevity’) will be developed followingly. We are acting intensively and with dispatch to proceed the production of new generation drugs and direct them to clinical trials.

Currently we are at the stage of the 3rd investment round and are just selecting a strategic investor and investors willing to go with us onward. The next step is the construction of an ultramodern culturomic-genomic laboratory and work on the isolation and synthesis of biotherapeutics.

Link to the interview with the CEO, Jarosław Biliński, MD PhD.